Lukas Biomedical Inc. (TPEX:6814)
Taiwan · Delayed Price · Currency is TWD 19.00
+0.70 (3.83%)
Sep 15, 2026, 1:56 PM CST
Lukas Biomedical Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 170.01 | 179.49 | 189.83 | 231.83 | 184.79 | 157.62 |
Revenue Growth | -5.28% | -5.44% | -18.12% | 25.46% | 17.24% | -13.11% |
Gross Profit Gross Profit Growth | 101.81 | 107.87 | 113.12 | 133.89 | 97.91 | 96.06 |
Operating Income Operating Income Growth | -87.15 | -81.16 | -92.14 | -43.56 | -48.47 | -43.06 |
Net Income Net Income Growth | -92.05 | -85.63 | -94.38 | -47.35 | -50.07 | -49.49 |
Earnings Per Share EPS Growth | -2.20 | -2.05 | -2.38 | -1.28 | -1.36 | -1.51 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Medical Management Operations Medical Management Operations Growth | 46.97 | 47.26 | 54.71 | 57.43 | 69.63 | 84.63 |
e-Commerce Department e-Commerce Department Growth | 100.99 | 113.7 | 120.71 | 152.29 | 106.21 | 69.93 |
Pharmaceutical Market Development Department Pharmaceutical Market Development Department Growth | 22.06 | 18.54 | 14.42 | 22.09 | 8.95 | - |
Total Total Growth | 170.01 | 179.49 | 189.83 | 231.83 | 184.79 | 157.66 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 26.81 | 34.75 | 64.71 | 31.8 | 40.26 | 64.81 |
Total Debt Total Debt Growth | 248.75 | 156.02 | 115.2 | 125.86 | 112.22 | 221.31 |
Net Cash (Debt) Net Cash Growth | -221.94 | -121.27 | -50.49 | -94.06 | -71.96 | -156.5 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -5.30 | -2.90 | -1.28 | -2.55 | -1.96 | -4.76 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -66.75 | -61.43 | -70.54 | -11.75 | -7.44 | -16.16 |
Capital Expenditures CapEx Growth | -1.11 | -8.22 | -6.81 | -2.66 | -2.98 | -10.03 |
Free Cash Flow Free Cash Flow Growth | -67.87 | -69.64 | -77.35 | -14.41 | -10.41 | -26.18 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 59.88% | 60.09% | 59.59% | 57.75% | 52.98% | 60.95% |
Operating Margin | -51.26% | -45.22% | -48.54% | -18.79% | -26.23% | -27.32% |
Pretax Margin | -53.04% | -46.67% | -49.77% | -20.39% | -27.01% | -30.35% |
Profit Margin | -54.14% | -47.71% | -49.72% | -20.42% | -27.10% | -31.40% |
FCF Margin | -39.92% | -38.80% | -40.75% | -6.21% | -5.63% | -16.61% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 3.54 | 7.23 | 6.59 | 4.66 | 6.29 | 8.72 |